miR-204 is dysregulated in metastatic prostate cancer in vitro

Molecular Carcinogenesis

Volumn 55, Issue 2, 2016, Pages 131-147

  Todorova, Krassimira ^a   Metodiev, Metodi V ^b   Metodieva, Gergana ^b   Zasheva, Diana ^a   Mincheff, Milcho ^c   Hayrabedyan, Soren ^a  

^a BULGARIAN ACADEMY OF SCIENCES   (Bulgaria)

^b UNIVERSITY OF ESSEX   (United Kingdom)

^c National Hematology Hospital   (Bulgaria)

Author keywords

(MeSH); DNA Methylation; LTQ Orbitrap Velos Proteomics; Micro RNA; Oncogene Fusion; Transcription Factor

Indexed keywords

MICRORNA; MICRORNA 204; PROTEIN C MYB; PROTEOME; SMALL INTERFERING RNA; TRANSCRIPTION FACTOR; TRANSCRIPTION FACTOR ETS 1; TRANSCRIPTION FACTOR RUNX2; UNCLASSIFIED DRUG; ERG PROTEIN, HUMAN; ETS1 PROTEIN, HUMAN; MIRN204 MICRORNA, HUMAN; ONCOPROTEIN; RUNX2 PROTEIN, HUMAN; TRANSACTIVATOR PROTEIN;

ARTICLE; BONE MARROW METASTASIS; CARCINOGENESIS; CELL DIFFERENTIATION; CELL LINEAGE; CONTROLLED STUDY; DISEASE COURSE; DNA METHYLATION; GENE DISRUPTION; GENE EXPRESSION; GENE REARRANGEMENT; GENE SILENCING; GENETIC TRANSFECTION; GENOMIC INSTABILITY; IN VITRO STUDY; LNCAP CELL LINE; LUCIFERASE ASSAY; LYMPH NODE METASTASIS; MOLECULAR PATHOLOGY; NCI H660 CELL LINE; ONCOGENE C MYB; PC3 CELL LINE; POSITIVE FEEDBACK; PRIORITY JOURNAL; PROSTATE CANCER; PROSTATE CANCER CELL LINE; PROTEIN EXPRESSION; PROTEIN STABILITY; REGULATORY MECHANISM; RNA SPLICING; VCAP CELL LINE; ALTERNATIVE RNA SPLICING; CHEMISTRY; GENE EXPRESSION REGULATION; GENETICS; HUMAN; MALE; METABOLISM; METASTASIS; PROSTATE TUMOR; TUMOR CELL LINE;

ALTERNATIVE SPLICING; CELL LINE, TUMOR; CORE BINDING FACTOR ALPHA 1 SUBUNIT; DNA METHYLATION; GENE EXPRESSION REGULATION, NEOPLASTIC; HUMANS; IN VITRO TECHNIQUES; MALE; MICRORNAS; NEOPLASM METASTASIS; ONCOGENE PROTEINS, FUSION; PROSTATIC NEOPLASMS; PROTEIN STABILITY; PROTEOME; PROTO-ONCOGENE PROTEIN C-ETS-1; PROTO-ONCOGENE PROTEINS C-MYB; TRANS-ACTIVATORS;

EID: 84955210754     PISSN: 08991987     EISSN: 10982744     Source Type: Journal    
DOI: 10.1002/mc.22263     Document Type: Article

References (70)

1. Ribarska T, Goering W, Droop J, Bastian KM, Ingenwerth M, Schulz WA. Deregulation of an imprinted gene network in prostate cancer. Epigenetics 2014; 9:704-717.
2. Aytes A, Mitrofanova A, Lefebvre C, et al. Cross-species regulatory network analysis identifies a synergistic interaction between FOXM1 and CENPF that drives prostate cancer malignancy. Cancer cell 2014; 25:638-651.
3. Savli H, Szendroi A, Romics I, Nagy B. Gene network and canonical pathway analysis in prostate cancer: A microarray study. Exp Mol Med 2008; 40:176-185.
4. Wang L, Tang H, Thayanithy V, et al. Gene networks and microRNAs implicated in aggressive prostate cancer. Cancer Res 2009; 69:9490-9497.
5. Majumdar S, Buckles E, Estrada J, Koochekpour S. Aberrant DNA methylation and prostate cancer. Curr Genomics 2011; 12:486-505.
6. Das PM, Singal R. DNA methylation and cancer. J Clin Oncol 2004; 22:4632-4642.
7. Hirashima K, Migita T, Sato S, Muramatsu Y, Ishikawa Y, Seimiya H. Telomere length influences cancer cell differentiation in vivo. Mol Cell Biol 2013; 33:2988-2995.
8. Srivastava SK, Bhardwaj A, Singh S, et al. Myb overexpression overrides androgen depletion-induced cell cycle arrest and apoptosis in prostate cancer cells, and confers aggressive malignant traits: Potential role in castration resistance. Carcinogenesis 2012; 33:1149-1157.
9. Hawksworth D, Ravindranath L, Chen Y, et al. Overexpression of C-MYC oncogene in prostate cancer predicts biochemical recurrence. Prostate cancer Prostatic Dis 2010; 13:311-315.
10. Tenen DG. Disruption of differentiation in human cancer: AML shows the way. Nat Rev Cancer 2003; 3:89-101.
11. Rosenbauer F, Tenen DG. Transcription factors in myeloid development: Balancing differentiation with transformation. Nature Rev Immunol 2007; 7:105-117.
12. Gery S, Koeffler HP. Transcription factors in hematopoietic malignancies. Curr Opin Genetics Dev 2007; 17:78-83.
13. Koschmieder S, Tenen D. Transcription Factors in Cancer Stem Cells of the Hematopoietic Lineage. In: Teicher BA, Bagley RG, editors. Stem Cells and Cancer, Cancer Drug Discovery and Development. Humana. 2009. pp. 75-83.
14. Goldberg L, Tijssen MR, Birger Y, et al. Genome-scale expression and transcription factor binding profiles reveal therapeutic targets in transgenic ERG myeloid leukemia. Blood 2013; 122:2694-2703.
15. Tomlins SA, Rhodes DR, Perner S, et al. Recurrent fusion of TMPRSS2 and ETS transcription factor genes in prostate cancer. Science 2005; 310:644-648.
16. Kumar A, Shendure J, Nelson PS. Genome interrupted: Sequencing of prostate cancer reveals the importance of chromosomal rearrangements. Genome Med 2011; 3:23.
17. Berger MF, Lawrence MS, Demichelis F, et al. The genomic complexity of primary human prostate cancer. Nature 2011; 470:214-220.
18. Lohr JG, Adalsteinsson VA, Cibulskis K, et al. Whole-exome sequencing of circulating tumor cells provides a window into metastatic prostate cancer. Nat Biotechnol 2014; 32:479-484.
19. Oberley LW, Oberley TD, Buettner GR. Cell differentiation, aging and cancer: The possible roles of superoxide and superoxide dismutases. Med Hypotheses 1980; 6:249-268.
20. Thiery JP. Epithelial-mesenchymal transitions in tumour progression. Nature Rev Cancer 2002; 2:442-454.
21. Thiery J, Dorothee G, Haddada H, et al. Potentiation of a tumor cell susceptibility to autologous CTL killing by restoration of wild-type p53 function. J Immunol 2003; 170:5919-5926.
22. Zhu ML, Kyprianou N. Role of androgens and the androgen receptor in epithelial-mesenchymal transition and invasion of prostate cancer cells. FASEB J 2010; 24:769-777.
23. Huber MA, Kraut N, Beug H. Molecular requirements for epithelial-mesenchymal transition during tumor progression. Curr Opin Cell Biol 2005; 17:548-558.
24. Cho RJ, Huang M, Campbell MJ, et al. Transcriptional regulation and function during the human cell cycle. Nat Genet 2001; 27:48-54.
25. Sun Y, Koo S, White N, et al. Development of a micro-array to detect human and mouse microRNAs and characterization of expression in human organs. Nucleic Acids Res 2004; 32:e188.
26. Lagos-Quintana M, Rauhut R, Yalcin A, Meyer J, Lendeckel W, Tuschl T. Identification of tissue-specific microRNAs from mouse. Curr Biol 2002; 12:735-739.
27. Palmieri D, D'Angelo D, Valentino T, et al. Downregulation of HMGA-targeting microRNAs has a critical role in human pituitary tumorigenesis. Oncogene 2012; 31:3857-3865.
28. Lin J, Cao Q, Zhang J, et al. MicroRNA expression patterns in indeterminate inflammatory bowel disease. Mod Pathol 2013; 26:148-154.
29. Karaivanov M, Todorova K, Kuzmanov A, Hayrabedyan S. Quantitative immunohistochemical detection of the molecular expression patterns in proliferative inflammatory atrophy. J Mol Histol 2007; 38:1-11.
30. Todorova K, Ignatova I, Tchakarov S, et al. Humoral immune response in prostate cancer patients after immunization with gene-based vaccines that encode for a protein that is proteasomally degraded. Cancer Immun 2005; 5:1.
31. Todorova K, Zoubak S, Mincheff M, Kyurkchiev S. Biochemical nature and mapping of PSMA epitopes recognized by human antibodies induced after immunization with gene-based vaccines. Anticancer Res 2005; 6C:4727-4732.
32. Todorova K, Mincheff M, Hayrabedyan S, et al. Fundamental role of microRNAs in androgen-dependent male reproductive biology and prostate cancerogenesis. Am J Reprod Immunol 2013; 69:100-104.
33. Imam JS, Plyler JR, Bansal H, et al. Genomic loss of tumor suppressor miRNA-204 promotes cancer cell migration and invasion by activating AKT/mTOR/Rac1 signaling and actin reorganization. PloS one 2012; 7:e52397.
34. Turner DP, Findlay VJ, Moussa O, et al. Mechanisms and functional consequences of PDEF protein expression loss during prostate cancer progression. Prostate 2011; 71:1723-1735.
35. Nicolaides NC, Gualdi R, Casadevall C, Manzella L, Calabretta B. Positive autoregulation of c-myb expression via Myb binding sites in the 5' flanking region of the human c-myb gene. Mol Cell Biol 1991; 11:6166-6176.
36. Kalkbrenner F, Guehmann S, Moelling K. Transcriptional activation by human c-myb and v-myb genes. Oncogene 1990; 5:657-661.
37. Tam W, Ben-Yehuda D, Hayward WS. Bic, a novel gene activated by proviral insertions in avian leukosis virus-induced lymphomas, is likely to function through its noncoding RNA. Mol Cell Biol 1997; 17:1490-1502.
38. Shiozawa Y, Pedersen EA, Havens AM, et al. Human prostate cancer metastases target the hematopoietic stem cell niche to establish footholds in mouse bone marrow. J Clin Invest 2011; 121:1298-1312.
39. Akech J, Wixted JJ, Bedard K, et al. Runx2 association with progression of prostate cancer in patients: Mechanisms mediating bone osteolysis and osteoblastic metastatic lesions. Oncogene 2010; 29:811-821.
40. Goloudina AR, Tanoue K, Hammann A, et al. Wip1 promotes RUNX2-dependent apoptosis in p53-negative tumors and protects normal tissues during treatment with anticancer agents. Proc Natl Acad Sci USA 2012; 109:E68-E75.
41. Zaidi SK, Pande S, Pratap J, et al. Runx2 deficiency and defective subnuclear targeting bypass senescence to promote immortalization and tumorigenic potential. Proc Natl Acad Sci USA 2007; 104:19861-19866.
42. Huang J, Zhao L, Xing L, Chen D. MicroRNA-204 regulates Runx2 protein expression and mesenchymal progenitor cell differentiation. Stem cells 2010; 28:357-364.
43. Zhang Y, Xie RL, Croce CM, et al. A program of microRNAs controls osteogenic lineage progression by targeting transcription factor Runx2. Proc Natl Acad Sci USA 2011; 108:9863-9868.
44. Markus MA, Gerstner RB, Draper DE, Torchia DA. Refining the overall structure and subdomain orientation of ribosomal protein S4 delta41 with dipolar couplings measured by NMR in uniaxial liquid crystalline phases. J Mol Biol 1999; 292:375-387.
45. Metodieva G, Nogueira-de-Souza NC, Greenwood C, et al. CD74-dependent deregulation of the tumor suppressor scribble in human epithelial and breast cancer cells. Neoplasia 2013; 15:660-668.
46. Cox J, Mann M. MaxQuant enables high peptide identification rates, individualized p. p. b. -range mass accuracies and proteome-wide protein quantification. Nat Biotechnol 2008; 26:1367-1372.
47. Benjamini Y, Hochberg Y. Controlling the false discovery rate: A practical and powerful approach to multiple testing. J R Stat Soc Series B 1995; 57:289-300.
48. Attard G, Clark J, Ambroisine L, et al. Duplication of the fusion of TMPRSS2 to ERG sequences identifies fatal human prostate cancer. Oncogene 2008; 27:253-263.
49. Narod SA, Seth A, Nam R. Fusion in the ETS gene family and prostate cancer. Br J Cancer 2008; 99:847-851.
50. Yin L, Rao P, Elson P, Wang J, Ittmann M, Heston WD. Role of TMPRSS2-ERG gene fusion in negative regulation of PSMA expression. PLoS One 2011; 6:e21319.
51. Sanges C, Scheuermann C, Zahedi RP, et al. Raf kinases mediate the phosphorylation of eukaryotic translation elongation factor 1A and regulate its stability in eukaryotic cells. Cell Death Dis 2012; 3:e276.
52. Wang FE, Zhang C, Maminishkis A, et al. MicroRNA-204/211 alters epithelial physiology. FASEB J 2010; 24:1552-1571.
53. Findlay VJ, Turner DP, Moussa O, Watson DK. MicroRNA-mediated inhibition of prostate-derived Ets factor messenger RNA translation affects prostate-derived Ets factor regulatory networks in human breast cancer. Cancer Res 2008; 68:8499-8506.
54. Bussemakers MJ, van Bokhoven A, Verhaegh GW, et al. DD3: A new prostate-specific gene, highly overexpressed in prostate cancer. Cancer Res 1999; 23:5975-5979.
55. Schmeier S, Schaefer U, Essack M, Bajic VB. Network analysis of microRNAs and their regulation in human ovarian cancer. BMC syst Biol 2011; 5:183.
56. Bao W, Wang HH, Tian FJ, et al. A TrkB-STAT3-miR-204-5p regulatory circuitry controls proliferation and invasion of endometrial carcinoma cells. Mol Cancer 2013; 12:155.
57. White NM, Khella HW, Grigull J, et al. MiRNA profiling in metastatic renal cell carcinoma reveals a tumour-suppressor effect for miR-215. Br J Cancer 2011; 105:1741-1749.
58. van der Deen M, Akech J, Wang T, et al. The cancer-related Runx2 protein enhances cell growth and responses to androgen and TGFbeta in prostate cancer cells. J Cell Biochem 2010; 109:828-837.
59. Brubaker KD, Vessella RL, Brown LG, Corey E. Prostate cancer expression of runt-domain transcription factor Runx2, a key regulator of osteoblast differentiation and function. Prostate 2003; 56:13-22.
60. Browne G, Nesbitt H, Ming L, et al. Bicalutamide-induced hypoxia potentiates RUNX2-mediated Bcl-2 expression resulting in apoptosis resistance. Br J Cancer 2012; 107:1714-1721.
61. Baniwal SK, Khalid O, Gabet Y, et al. Runx2 transcriptome of prostate cancer cells: Insights into invasiveness and bone metastasis. Mol Cancer 2010; 9:258.
62. Baniwal SK, Khalid O, Sir D, Buchanan G, Coetzee GA, Frenkel B. Repression of Runx2 by androgen receptor (AR) in osteoblasts and prostate cancer cells: AR binds Runx2 and abrogates its recruitment to DNA. Mol Endocrinol 2009; 23:1203-1214.
63. Baniwal SK, Little GH, Chimge NO, Frenkel B. Runx2 controls a feed-forward loop between androgen and prolactin-induced protein (PIP) in stimulating T47D cell proliferation. J Cell Physiol 2012; 227:2276-2282.
64. Liaw HH, Lin CC, Juan HF, Huang HC. Differential microRNA regulation correlates with alternative polyadenylation pattern between breast cancer and normal cells. PloS one 2013; 8:e56958.
65. Ren S, Peng Z, Mao JH, et al. RNA-seq analysis of prostate cancer in the Chinese population identifies recurrent gene fusions, cancer-associated long noncoding RNAs and aberrant alternative splicings. Cell Res 2012; 22:806-821.
66. Voutsadakis IA, Papandreou CN. The ubiquitin-proteasome system in prostate cancer and its transition to castration resistance. Urol Oncol 2012; 30:752-761.
67. Wen H, Andrejka L, Ashton J, Karess R, Lipsick JS. Epigenetic regulation of gene expression by Drosophila Myb and E2F2-RBF via the Myb-MuvB/dREAM complex. Genes Dev 2008; 22:601-614.
68. Alumkal JJ, Herman JG. Distinct epigenetic mechanisms distinguish TMPRSS2-ERG fusion-positive and -negative prostate cancers. Cancer Discov 2012; 2:979-981.
69. Borno ST, Fischer A, Kerick M, et al. Genome-wide DNA methylation events in TMPRSS2-ERG fusion-negative prostate cancers implicate an EZH2-dependent mechanism with miR-26a hypermethylation. Cancer Discov 2012; 2:1024-1035.
70. Iljin K, Wolf M, Edgren H, et al. TMPRSS2 fusions with oncogenic ETS factors in prostate cancer involve unbalanced genomic rearrangements and are associated with HDAC1 and epigenetic reprogramming. Cancer Res 2006; 66:10242-10246.